Pennsylvania is currently home to 3310 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
Recruiting
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/04/2025
Locations: Eye Care Specialists, Kingston, Pennsylvania
Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
Recruiting
This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered once weekly. The study consists of 2 parts: Part 1 and Part 2. Six participants (Cohort 1) will participate in both Part 1 and Part 2, and 14 participants (Cohort 2) will be added for Part 2.
Gender:
MALE
Ages:
Between 4 years and 14 years
Trial Updated:
06/04/2025
Locations: University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
Conditions: Duchenne Muscular Dystrophy
Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES
Recruiting
This is a pragmatic clinical trial that will study the effect of a radiomics-based computer-aided diagnosis (CAD) tool on clinicians' management of pulmonary nodules (PNs) compared to usual care. Adults aged 35-89 years with 8-30mm PNs evaluated at Penn Medicine PN clinics will undergo 1:1 randomization to one of two groups, defined by the PN malignancy risk stratification strategy used by evaluating clinicians: 1) usual care or 2) usual care + use of a radiomics-based CAD tool.
Gender:
ALL
Ages:
Between 35 years and 89 years
Trial Updated:
06/04/2025
Locations: Penn Medicine University City, Philadelphia, Pennsylvania
Conditions: Lung Cancer, Pulmonary Nodule, Solitary
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
06/04/2025
Locations: Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania
Conditions: Breast Cancer
PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial
Recruiting
This clinical trial examines positron emission tomography (PET)/computed tomography (CT) in evaluating cardiac radiation damage in patients with lung or esophageal cancer. As part of the treatment for lung or esophageal cancer, patients will undergo radiation therapy. Sometimes, during this treatment, the heart is also subjected to some radiation which could affect its function, either increasing or decreasing the function. It is not known the consequences of this change nor is it known if docto... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Lung Carcinoma, Esophageal Carcinoma
XTX301 in Patients With Advanced Solid Tumors
Recruiting
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Advanced Solid Tumor
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recruiting
This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with excess blasts. Blasts are immature blood cells. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm
Otoferlin Gene-mediated Hearing Loss Natural History Study
Recruiting
This is a retrospective and prospective longitudinal study in participants with Otoferlin Gene-Mediated Hearing Loss.
Gender:
ALL
Ages:
44 years and below
Trial Updated:
06/04/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Sensorineural Hearing Loss, Bilateral
A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer
Recruiting
This clinical trial evaluates automated breast ultrasound (ABUS) and handheld ultrasound (HHUS) for the screening of women who have undergone breast reconstruction after breast cancer. Ultrasounds use high-frequency sound waves to create pictures of internal organs and tissues. ABUS has been found to be equal to HHUS for whole breast screening, but no data exist on its use for screening of reconstructed patients. This clinical trial evaluates the feasibility of using ABUS versus HHUS to screen w... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Malignant Breast Neoplasm
Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
Recruiting
This phase II trial tests whether contrast-enhanced ultrasound can predict the response of bile duct cancer to targeted radiotherapy (radioembolization treatment). Contrast-enhanced ultrasound uses gas microbubbles that may provide enhancement on ultrasound. It is also possible to pop these microbubbles using ultrasound imaging. Tumors that experience popping of these microbubbles may be easier to kill with radiotherapies. Therefore, this trial may also help doctors see if ultrasound-triggered m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Intrahepatic Cholangiocarcinoma
MiSight 1 Day Safety Post-Approval Study
Recruiting
The purpose of this post-approval study is to confirm the safety of daily disposable soft contact lens wear among the intended patient population for the MiSight 1 Day lens in the US.
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
06/04/2025
Locations: Nittany Eye Associates, LLC, State College, Pennsylvania
Conditions: Myopia
Collection of Samples USOPTIVAL Study
Recruiting
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
Gender:
ALL
Ages:
Between 45 years and 84 years
Trial Updated:
06/04/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Colorectal Cancer (CRC), Advanced Adenomas (AA)